MX2018015252A - Inhibidores de la interaccion de menina-leucemia de linaje mixto. - Google Patents

Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Info

Publication number
MX2018015252A
MX2018015252A MX2018015252A MX2018015252A MX2018015252A MX 2018015252 A MX2018015252 A MX 2018015252A MX 2018015252 A MX2018015252 A MX 2018015252A MX 2018015252 A MX2018015252 A MX 2018015252A MX 2018015252 A MX2018015252 A MX 2018015252A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
mll
interaction
mll interaction
Prior art date
Application number
MX2018015252A
Other languages
English (en)
Inventor
Yuan Jing
Marcus Andrew
Dong Chengguo
Fan Yi
Jia Lanqi
A Claremon David
Zhuang Linghang
Cacatian Salvacion
Wayne Dillard Lawrence
D Lotesta Stephen
Morales-Ramos Angel
B Singh Suresh
Venkatraman Shankar
Zheng Yajun
D Parent Stephan
l houston Travis
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of MX2018015252A publication Critical patent/MX2018015252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invencion se refiere a inhibidores de la interaccion de menina con MLL y proteinas de fusion de MLL, composiciones farmaceuticas que contienen los mismos, y su uso en el tratamiento de cancer y otras enfermedades mediadas por la interaccion de menina-MLL.
MX2018015252A 2016-06-10 2017-06-08 Inhibidores de la interaccion de menina-leucemia de linaje mixto. MX2018015252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348496P 2016-06-10 2016-06-10
PCT/US2017/036506 WO2017214367A1 (en) 2016-06-10 2017-06-08 Inhibitors of the menin-mll interaction

Publications (1)

Publication Number Publication Date
MX2018015252A true MX2018015252A (es) 2019-04-25

Family

ID=59325631

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018015252A MX2018015252A (es) 2016-06-10 2017-06-08 Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2021003939A MX2021003939A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2023002982A MX2023002982A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021003939A MX2021003939A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2023002982A MX2023002982A (es) 2016-06-10 2018-12-07 Inhibidores de la interaccion de menina-leucemia de linaje mixto.

Country Status (21)

Country Link
US (3) US10683302B2 (es)
EP (2) EP3805215A1 (es)
JP (3) JP7007302B2 (es)
KR (2) KR20220123727A (es)
CN (1) CN109743875B (es)
AU (2) AU2017278950B2 (es)
BR (2) BR122024002146A2 (es)
CA (1) CA3024180A1 (es)
CY (1) CY1124834T1 (es)
DK (1) DK3468966T3 (es)
ES (1) ES2831084T3 (es)
HR (1) HRP20201771T1 (es)
HU (1) HUE051451T2 (es)
IL (3) IL298381A (es)
LT (1) LT3468966T (es)
MX (3) MX2018015252A (es)
PL (1) PL3468966T3 (es)
PT (1) PT3468966T (es)
SI (1) SI3468966T1 (es)
WO (1) WO2017214367A1 (es)
ZA (1) ZA201900150B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
MX2018011105A (es) 2016-03-16 2018-11-22 Kura Oncology Inc Inhibidores sustituidos de menina-mll y metodos de uso.
KR20190015275A (ko) 2016-05-02 2019-02-13 더 리젠츠 오브 더 유니버시티 오브 미시간 메닌 억제제로서의 피페리딘
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
ES2901227T3 (es) 2016-12-15 2022-03-21 Janssen Pharmaceutica Nv Inhibidores de azepano de la interacción menina-MLL
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
KR20190133224A (ko) 2017-03-31 2019-12-02 더 리젠츠 오브 더 유니버시티 오브 미시간 공유 메닌 억제제로서의 피페리딘
JP7168556B2 (ja) * 2017-04-10 2022-11-09 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
WO2019120209A1 (en) * 2017-12-20 2019-06-27 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-mll interaction
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
BR112021002090A8 (pt) 2018-08-27 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Derivado azabicíclico opticamente ativo
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
WO2020114474A1 (zh) * 2018-12-06 2020-06-11 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
MX2021006696A (es) 2018-12-06 2021-07-07 Daiichi Sankyo Co Ltd Derivado de cicloalcano-1,3-diamina.
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
UY38907A (es) * 2019-10-09 2021-05-31 Novartis Ag Compuestos derivados de 2–azaespiro[3.4]octano como agonistas de m4 y composiciones de los mismos
CA3156320A1 (en) 2019-10-09 2021-04-15 Novartis Ag 2-AZASPIRO[3,4] OCTANE DERIVATIVES USED AS M4 AGONISTS
WO2021121327A1 (en) * 2019-12-19 2021-06-24 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
JP7454520B2 (ja) 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
CA3178691A1 (en) * 2020-04-07 2021-10-14 Syndax Pharmaceuticals, Inc. Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения
CN117321049A (zh) 2021-05-08 2023-12-29 詹森药业有限公司 取代的螺环衍生物
WO2022237627A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
CA3215313A1 (en) * 2021-05-11 2022-11-17 Nikki DASKALAKIS Combination therapies
IL308333A (en) * 2021-05-11 2024-01-01 Janssen Pharmaceutica Nv Combined treatments
KR20240047338A (ko) * 2021-05-14 2024-04-12 신닥스 파마슈티컬스, 인크. 메닌-mll 상호작용의 억제제
US20230250096A1 (en) 2021-06-01 2023-08-10 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
WO2022253309A1 (zh) * 2021-06-03 2022-12-08 首药控股(北京)股份有限公司 取代的杂环化合物及其应用
WO2022257047A1 (en) * 2021-06-09 2022-12-15 Acerand Therapeutics (Hong Kong) Limited Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof
IL309359A (en) * 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexane-3-yl)- salt 6,2-diazaspiro[4.3]octan-6-yl)-4,2,1-triazin-6-yl)oxy) benzamide besylate for the treatment of diseases such as cancer
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN113769098B (zh) * 2021-09-22 2022-09-30 中国医学科学院肿瘤医院深圳医院 MLL-menin抑制剂组合物在制备抗肝癌药物中的应用
TW202333690A (zh) * 2021-12-03 2023-09-01 大陸商燁輝醫藥科技（上海）有限公司 羰基取代的二氮雜螺化合物及其用途
WO2023125928A1 (zh) * 2021-12-31 2023-07-06 成都先导药物开发股份有限公司 Menin抑制剂及其用途
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2012170976A2 (en) 2011-06-10 2012-12-13 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
JP2016512514A (ja) 2013-03-13 2016-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3394064A1 (en) 2015-12-22 2018-10-31 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction

Also Published As

Publication number Publication date
BR122024002146A2 (pt) 2024-03-05
CN109743875B (zh) 2022-04-29
ES2831084T3 (es) 2021-06-07
AU2021258089B2 (en) 2024-01-25
PT3468966T (pt) 2020-11-10
CN109743875A (zh) 2019-05-10
HRP20201771T1 (hr) 2021-02-19
JP7461390B2 (ja) 2024-04-03
KR102436430B1 (ko) 2022-08-24
JP2019517548A (ja) 2019-06-24
EP3805215A1 (en) 2021-04-14
WO2017214367A1 (en) 2017-12-14
PL3468966T3 (pl) 2021-04-06
US20230174541A1 (en) 2023-06-08
MX2021003939A (es) 2021-05-27
AU2017278950B2 (en) 2021-07-29
JP7007302B2 (ja) 2022-01-24
IL283267B (en) 2022-12-01
IL298381A (en) 2023-01-01
US11479557B2 (en) 2022-10-25
SI3468966T1 (sl) 2021-03-31
HUE051451T2 (hu) 2021-03-01
IL263586B (en) 2021-06-30
RU2019100040A3 (es) 2020-07-15
CY1124834T1 (el) 2022-07-22
US20210053974A1 (en) 2021-02-25
IL263586A (en) 2019-01-31
JP2022058514A (ja) 2022-04-12
MX2023002982A (es) 2023-04-10
EP3468966A1 (en) 2019-04-17
JP2024045176A (ja) 2024-04-02
LT3468966T (lt) 2021-02-25
CA3024180A1 (en) 2017-12-14
ZA201900150B (en) 2023-04-26
AU2021258089A1 (en) 2021-11-25
DK3468966T3 (da) 2020-11-09
IL283267B2 (en) 2023-04-01
BR112018075260A2 (pt) 2019-03-12
KR20190017012A (ko) 2019-02-19
AU2017278950A1 (en) 2019-01-03
US20190144459A1 (en) 2019-05-16
IL283267A (en) 2021-07-29
RU2019100040A (ru) 2020-07-13
US10683302B2 (en) 2020-06-16
KR20220123727A (ko) 2022-09-08
EP3468966B1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12017501481B1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2017009608A (es) Compuestos anticancerigenos.
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
EA202190877A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr